Intelligent Bio Solutions Clears Key FDA Hurdle with Flawless Security Testing
Summary
Intelligent Bio Solutions Inc. announced the successful completion of penetration testing for its upcoming FDA 510(k) submission, identifying no major security vulnerabilities. This positive development strengthens the company's regulatory submission and is a critical step towards potential FDA clearance, which would open significant revenue opportunities in the multi-billion-dollar U.S. drug screening market. This progress is particularly important given the company's recent "going concern" warning and material weaknesses in internal controls, as successful product commercialization is vital for its long-term viability. Investors will now watch for further updates on the FDA 510(k) submission timeline and eventual clearance.
At the time of this announcement, INBS was trading at $2.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $2.42 to $24.90. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.